Table 1.
Targeted LC-MS NAD+ metabolome of primary myotubes treated with NR (0.5 mM) and/or FK866 (100 nM).
| Metabolites (pmol/mg) | Control | NR | FK866 | FK866 + NR |
|---|---|---|---|---|
| NAD(H) | 790.2 ± 54.3 | 1968.1 ± 518.1*† | 253.8 ± 25.7 | 1564.4 ± 207.6† |
| NADP(H) | 90.5 ± 3.1 | 186.4 ± 62.1 | 55.1 ± 23.5 | 98.4 ± 20.1 |
| NR | 4.9 ± 0.6 | 73.6 ± 9.5*† | 9.9 ± 2.0 | 112.1 ± 11.2*† |
| NAM | 834.2 ± 29.8 | 1064.2 ± 172.4† | 354.1 ± 43.3* | 973.1 ± 75.8† |
| ADPr | 535.3 ± 198.4 | 400.2 ± 54.1 | 326.6 ± 86 | 537.5 ± 104.3 |
| NMN | ND | 107.9 ± 26.5*† | 3.8 ± 0.7 | 79.6 ± 12.1*† |
| Na | ND | ND | ND | ND |
| NaR | ND | 1.7 ± 0.2*† | 0.1 ± 0.1 | 1.9 ± 0.2*† |
| NaAD | ND | 14.9 ± 5.6*† | ND | 8.4 ± 2 |
| NaMN | ND | ND | ND | ND |
*Significant to control, †significant to FK866 treated, n = 3.